Inventor · disambiguated record
Lykke Pedersen
Also filed as: PEDERSEN LYKKE
21 granted patents·36 pending applications·47 citations·filing 2016–2025
94Inventor score
Files withHOFFMANN LA ROCHE40ROCHE INNOVATION CT COPENHAGEN AS14NEUMIRNA THERAPEUTICS APS2HOFFMANN LA ROCHE INC1
Top patents by PatentIndex Score
57 records- 0195US12259380B2Oligonucleotides for inducing paternal UBE3A expressionHOFFMANN LA ROCHE·Filed 2023·Granted Mar 25, 2025·2 cites·26 claims
- 0295US11852627B2Oligonucleotides for inducing paternal UBE3A expressionHOFFMANN LA ROCHE·Filed 2022·Granted Dec 26, 2023·3 cites·11 claims
- 0394US11320421B2Oligonucleotides for inducing paternal UBE3A expressionHOFFMANN LA ROCHE·Filed 2020·Granted May 3, 2022·3 cites·16 claims
- 0494US10739332B2Oligonucleotides for inducing paternal UBE3A expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Granted Aug 11, 2020·6 cites·5 claims
- 0593US10718753B2Oligonucleotides for inducing paternal UBE3A expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Granted Jul 21, 2020·5 cites·9 claims
- 0691US10953034B2Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infectionHOFFMANN LA ROCHE·Filed 2018·Granted Mar 23, 2021·5 cites·24 claims
- 0790US12303525B2Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infectionHOFFMANN LA ROCHE·Filed 2022·Granted May 20, 2025·1 cites·41 claims
- 0890US10494633B2Oligonucleotides for inducing paternal UBE3A expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2016·Granted Dec 3, 2019·8 cites·24 claims
- 0989US10829555B2Oligonucleotides for reduction of PD-L1 expressionHOFFMANN LA ROCHE·Filed 2020·Granted Nov 10, 2020·3 cites·14 claims
- 1088US11484546B2Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infectionHOFFMANN LA ROCHE·Filed 2019·Granted Nov 1, 2022·3 cites·36 claims
- 1187US10745480B2Oligonucleotides for reduction of PD-L1 expressionHOFFMANN LA ROCHE·Filed 2019·Granted Aug 18, 2020·3 cites·30 claims
- 1286US11466081B2Oligonucleotides for reduction of PD-L1 expressionHOFFMANN LA ROCHE·Filed 2020·Granted Oct 11, 2022·2 cites·22 claims
- 1385US11534452B2Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infectionHOFFMANN LA ROCHE·Filed 2017·Granted Dec 27, 2022·2 cites·18 claims
- 1477US2023210887A1Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infectionHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1575US2025319114A1NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTIONHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 1674US11542501B2Antisense oligonucleotides targeting ATXN3HOFFMANN LA ROCHE·Filed 2020·Granted Jan 3, 2023·1 cites·15 claims
- 1770US2024182898A1ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTELl EXPRESSIONHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1868US11898145B2Enhanced oligonucleotides for inhibiting RTEL1 expressionHOFFMANN LA ROCHE·Filed 2022·Granted Feb 13, 2024·0 cites·17 claims
- 1967US2024150758A1Use of fubp1 inhibitors for treating hepatitis b virus infectionHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2064US2023257748A1Use of a1cf inhibitors for treating hepatitis b virus infectionHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2163US2024294915A1Oligonucleotides for Modulating Apolipoprotein E4 ExpressionHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2263US2020157546A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2362US11066669B2Oligonucleotides for modulating ATXN2 expressionHOFFMANN LA ROCHE·Filed 2019·Granted Jul 20, 2021·0 cites·23 claims
- 2462US2025136990A1Antisense oligonucleotides targeting adenosine kinaseNEUMIRNA THERAPEUTICS APS·Filed 2022·Application pending·0 cites
- 2562US2022042022A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2661US2024240188A1Antisense oligonucleotides targeting adenosine kinaseNEUMIRNA THERAPEUTICS APS·Filed 2022·Application pending·0 cites
- 2759US11732262B2Use of FUBP1 inhibitors for treating hepatitis B virus infectionHOFFMANN—LA ROCHE INC·Filed 2020·Granted Aug 22, 2023·0 cites·10 claims
- 2859US2024167040A1Antisense oligonucleotideHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2958US12497621B2Oligonucleotides for modulating RTEL1 expressionHOFFMANN LA ROCHE·Filed 2021·Granted Dec 16, 2025·0 cites·8 claims
- 3057US11286485B2Oligonucleotides for modulating ATXN2 expressionHOFFMANN LA ROCHE·Filed 2020·Granted Mar 29, 2022·0 cites·14 claims
- 3157US2021214727A1Enhanced oligonucleotides for inhibiting scn9a expressionHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3256US2023118138A1Use of scamp3 inhibitors for treating hepatitis b virus infectionHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3356US2023193263A1Use of sbds inhibitors for treating hepatitis b virus infectionHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3456US2023122751A1Use of cops3 inhibitors for treating hepatitis b virus infectionHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3556US2020399641A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 3656US2023183692A1Use of sept9 inhibitors for treating hepatitis b virus infectionHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3756US2021261961A1Antisense oligonucleotides targeting tia1HOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 3855US2023060373A1Antisense Oligonucleotides Targeting ATXN3HOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 3955US2017283496A1Oligonucleotides for reduction of pd-l1 expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Application pending·0 cites
- 4054US2023212572A1Guanosine Analogues for Use in Therapeutics PolynucleotidesROCHE INNOVATION CT COPENHAGEN AS·Filed 2021·Application pending·0 cites
- 4153US2022177883A1Antisense Oligonucleotides Targeting ATXN3HOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4251US2023120063A1Use of saraf inhibitors for treating hepatitis b virus infectionHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 4351US2019365795A1Oligonucleotides for modulating atxn2 expressionHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 4450US2023054720A1Antisense Oligonucleotides Targeting ATXN3HOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4549US12116576B2Oligonucleotides for modulating SCN9A expressionHOFFMANN LA ROCHE·Filed 2020·Granted Oct 15, 2024·0 cites·16 claims
- 4649US2022031730A1Enhanced oligonucleotides for modulating fubp1 expressionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4748US2021095274A1Oligonucleotides for modulating pias4 expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Application pending·0 cites
- 4848US2021095275A1Oligonucleotides for modulating gsk3b expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Application pending·0 cites
- 4948US2020385714A1Oligonucleotides for modulating fndc3b expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Application pending·0 cites
- 5048US2019055564A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Lykke Pedersen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →